Clinical Trials Browser

Neoplasm Metastasis × spartalizumab × Dermatologic × Clear all

NCT03991130 2025-02-06

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

Phase 2 Terminated

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis